Investor Presentation First Nine Months of 2023
94
Investor presentation
First nine months of 2023
Novo Nordisk is expanding into other serious chronic diseases
Serious chronic diseases are associated with diabetes and obesity
New therapeutic areas represent patient populations with high
unmet medical needs
AD
Patients with AD live from 2 to 20
years from dementia onset
AD
Estimated patients
~85 million
70% of people with diabetes die
from atherosclerotic CVD
Estimated patients
CVD
40% of people hospitalised for
heart failure have diabetes
CVD
~520 million
Estimated patients
MASH
80% of people with MASH live with
obesity and 35% have diabetes
MASH
~25 million¹
CKD
•
40% of people with diabetes have
diabetic nephropathy and 50% have
obesity
CKD
~700 million³
Number of related deaths
-20 million annually
Diagnosis rate
-20%2
-20%
Novo NordiskⓇ
1Estes C et al. Hepatology, 2018; 2 Diagnosis rate is considered a major uncertainty to the forecast; ³Carney EF. Nat Rev Nephrol 2020;16:251
CVD: Cardiovascular disease; MASH: Metabolic dysfunction-associated steatohepatitis; CKD: Chronic kidney disease; AD: Alzheimer's Disease
Sources: Alzheimer's Association report: 2020 Alzheimer's disease facts and figures, 2020 (16:391-460), Diabetes Care 2005 Jan; 28(1): 164-176; Abera SF et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015, 2017;
Heart Disease and Stroke Statistics, American Heart Association, 2017; Williams CD et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy, 2011;
Addressing the global burden of chronic kidney disease through clinical and translational research, 2014View entire presentation